TALEN-Mediated Gene Mutagenesis in Rhesus and Cynomolgus Monkeys  by Liu, Hailiang et al.
Cell Stem Cell
Brief ReportTALEN-Mediated Gene Mutagenesis
in Rhesus and Cynomolgus Monkeys
Hailiang Liu,1,2,9 Yongchang Chen,1,3,4,9 Yuyu Niu,1,3,4,9 Kunshan Zhang,2,9 Yu Kang,1,3 Weihong Ge,6 Xiaojing Liu,2
Enfeng Zhao,2,8 Chencheng Wang,2 Shaoyun Lin,2 Bo Jing,2 Chenyang Si,1,3 Quan Lin,2,6 Xiaoying Chen,2,6 Haijun Lin,2
Xiuqiong Pu,1,3 Yingying Wang,2 Binlian Qin,2 Fang Wang,1,3 Hong Wang,1,3,4 Wei Si,1,3,4 Jing Zhou,2 Tao Tan,1,3,4
Tianqing Li,1,3,4 Shaohui Ji,1,3,4 Zhigang Xue,2 Yuping Luo,2 Liming Cheng,2 Qi Zhou,5 Siguang Li,2,* Yi Eve Sun,1,2,6,*
and Weizhi Ji1,3,7,*
1Yunnan Key Laboratory of Primate Biomedical Research, Kunming, 650500, China
2Translational Stem Cell Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200092, China
3Kunming Biomed International and National Engineering Research Center of Biomedicine and Animal Science, Kunming, 650500, China
4Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China
5State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China
6Department of Psychiatry and Biobehavioral Sciences, UCLA Medical School, Los Angeles, CA 90095, USA
7Life Science and Technology, Kunming University of Science and Technology, Kunming, 650224, China
8Shanghai Huadong Hospital, Shanghai, 200040, China
9These authors contributed equally to this work
*Correspondence: siguangli@163.com (S.L.), ysun@mednet.ucla.edu (Y.E.S.), wji@kbimed.com (W.J.)
http://dx.doi.org/10.1016/j.stem.2014.01.018SUMMARY
Recent advances in gene editing technology have
introduced the potential for application of mutagen-
esis approaches in nonhuman primates to model
human development and disease. Here we report
successful TALEN-mediated mutagenesis of an
X-linked, Rett syndrome (RTT) gene, methyl-CpG
binding protein 2 (MECP2), in both rhesus and cyno-
molgus monkeys. Microinjection of MECP2-target-
ing TALEN plasmids into rhesus and cynomolgus
zygotes leads to effective gene editing of MECP2
with no detected off-target mutagenesis. Male rhe-
sus (2) and cynomolgous (1) fetuses carrying
MECP2mutations in various tissues including testes
were miscarried during midgestation, consistent
with RTT-linked male embryonic lethality in humans.
One live delivery of a female cynomolgus monkey
occurred after 162 days of gestation, with abundant
MECP2mutations in peripheral tissues.We conclude
that TALEN-mediated mutagenesis can be an effec-
tive tool for genetic modeling of human disease in
nonhuman primates.
Nonhuman primates (NHPs) provide powerful experimentalmodels to study human development and disease because of
their genetic and physiological similarities to humans. Monkeys,
such as rhesus and cynomolgus macaques, are particularly
appropriate for studying cognitive functions and neurological
disorders as well as complex behaviors (Niu et al., 2010; Chen
et al., 2012a). To date, there have been only a few reported suc-
cesses in producing transgenic monkeys, all of which involved
virus-mediated gene transfer (Niu et al., 2010; Chan et al.,
2001; Chen et al., 2012b; Wolfgang et al., 2001; Yang et al.,
2008; Sasaki et al., 2009). Because germline-competent ESCsCand somatic cell nuclear transfer (SCNT) are not broadly
available for NHPs, recently developed gene editing technolo-
gies involving ZFNs, TALENs, and CRISPR/Cas9 offer new
opportunities for disease modeling (Mali et al., 2013; Moscou
and Bogdanove, 2009; Cho et al., 2013; Cong et al., 2013;
Wood et al., 2011; Deng et al., 2012; Takada et al., 2013).
Here, we applied TALENs to generate MECP2 mutant rhesus
and cynomolgus macaques from one-cell embryos. MECP2
is an X-linked, monoallelically expressed gene encoding a
methyl-CpG binding protein (Nan et al., 1998; Jones et al.,
1998; Skene et al., 2010). Loss-of-function mutations in
MECP2 generally lead to a neurodevelopmental disorder on
the autism spectrum known as Rett syndrome (RTT). In humans,
hemizygous loss-of-function mutations ofMECP2 in males leads
to embryonic lethality (Hagberg, 1985; Hagberg et al., 1983; Amir
et al., 1999), but in females random X chromosome inactivation
leads to graded chimerism of mutant and wild-type-allele-
expressing cells and a wide range of severities in RTT pheno-
type. In this study, we used TALEN-based mutagenesis to
generate a total of four rhesus and cynomolgous monkeys
carrying MECP2 mutations with chimerism. All three male
fetuses died during midgestation, consistent with the human
RTT male phenotype. To our knowledge, this is the first report
of targeted mutagenesis in monkeys with TALEN technology
for modeling of human disease.
The monkey MECP2 gene contains four exons, similar to that
of humans and mice (Figure 1A), with the methyl-CpG binding
domain (MBD) encoded by both exon 3 and exon 4 (Nan et al.,
1998). We decided to target exon 3 with three pairs of TALEN
constructs (Figure 1A) because exon 3 is the 50 most common
exon for the A and B form of the MECP2 transcripts, and our
aim was to disrupt the gene. These sites are conserved in
humans, so we initially used a luciferase reporter assay in 293T
cells to evaluate the efficacy of our TALEN-mediated mutagen-
esis approach (Figures S1A–S1C available online). In addition,
when these TALEN pairs were transfected individually into
Macaca fascicularis mesenchymal stem cells (MSCs) as well asell Stem Cell 14, 323–328, March 6, 2014 ª2014 Elsevier Inc. 323
Figure 1. MECP2 Mutant Monkey Fetuses Generated by TALEN
(A) Schematic of TALEN-targeting sites within monkeyMECP2 locus exon 3. The first nucleotide of exon 3 is numbered as 1, and the last nucleotide of exon 3 is
numbered 351. TALEN-targeting sequences are labeled as T1, T2, T3 (L, R).
(B) Summary of embryo transfer (ET) after TALEN injection in both rhesus and cynomolgous monkeys. #, embryos transferred between two-cell and blastocyst
stage; a, including one singleton and one twin; b, miscarriage happened on the 30th and 63rd/64th days after ET; c, one female cynomolgus was born alive after
162 days of gestation; d, one male cynomolus fetus was miscarried on the 92nd day of gestation.
(legend continued on next page)
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and S1E).
Because TALEN targeting efficiency could have cell-type
specificity, we decided to inject all three TALENpairs of targeting
plasmids either individually or in combination, together with
RAD51, into one-cell monkey zygotes. RAD51 was included to
enhance DNA repair following TALEN activity. We found that
compound targeting with all three pairs was the most effective
approach for creating MECP2 mutations. Comparing mRNA
and DNA versions (supercoiled/circular plasmids) of each
TALEN targeting constructs, at a dose of 5 pl of 2 ng/ml per
injected zygote, the DNA version appeared to be more effica-
cious in target editing. Thus circular plasmids were used for
future injections. Cytoplasmic injection of circular plasmid DNA
in one-cell embryos results in the prolonged episomal form of
plasmid-carried gene expression during early embryonic stages
(Iqbal et al., 2009), without genomic integration. If plasmid inte-
grations did occur, they can be easily detected by TALEN-
plasmid-specific PCR amplification from monkey genomic
DNA, especially from later stage fetuses, where free plasmids
would have been diluted by cell divisions. In our study, we did
not detect any plasmid integration (Figure S2A). With this
approach, the mutation rate of the manipulated embryos at the
MECP2 locus was within the range of 40%–50% when assayed
beyond the eight-cell stage (Figures S1F–S1H). Our approach,
with prolonged TALEN expression and action, is anticipated to
create a large repertoire of targeted MECP2 mutations, thus
maximizing the disruption of the target gene and increasing the
chance for generating mutations in the germline. If presented
with a replacement DNA target template carrying specific muta-
tions, this approach could also enhance homologous recombi-
nation to generate knockins. Although this type of approach is
not classically used to generate mutant animals, it could be
particularly advantageous when animal resources are limited,
as in the case of NHPs.
Because the TALEN-mediated mutation rate in early embryos
was reasonably high (40%–50%), we moved on to transferring
manipulated embryos into surrogate female monkeys. The sur-
rogate pregnancy rates were 28.6% (2/7) and 31.6% (6/19) for
rhesus and cynomolgus, respectively (Figure 1B). From seven
surrogate rhesus mothers that were transferred with three
embryos each, two became pregnant. One went through mis-
carriage at day 30 of gestation. The aborted embryo was not
collected. The second pregnant monkey with a twin pregnancy
went through miscarriage at day 63 of gestation with the first
fetus (A) followed by the second fetus (B) 24 hr later (Figure 1C).(C) Images and sex identification of the two aborted Rhesus monkey fetuses.
(D) Paternal andmaternal DNAs were subjected to Sanger sequencing and T7EN1
to cut. Thematernal alleles are heterogeneous (with one 217C allele and one 217T
arrows point at cleaved products).
(E) Positive T7EN1 cleavage results from themiscarriedmonkey fetuses’ tail, brain
(cleaved products are indicated by the bracket with a star).
(F) All detected point mutations were plotted based on their positions and mutatio
tail, brain, and testes of the two miscarried fetuses.
(G) Detrimental mutations (leading to early truncations or in-dels) detected in bra
(H) Mutation rates calculated from Sanger sequencing of MECP2 exon 3. From tot
and sequences with at least one mismatch. When the percentage of perfectly mat
in each tissue sequenced.
See also Figures S1 and S2 and Table S1.
CBoth fetuses were collected and analyzed. Using the
Y-chromosome-associated SRY gene as a male genetic marker,
we confirmed that both were males.
To determine whether the two miscarried male rhesus fetuses
contained MECP2 mutations, we used a T7EN1 cleavage assay
(Shen et al., 2013). To establish the validity of this assay, we PCR
amplified the entire MECP2 exon 3 from paternal and maternal
genomic DNAs. There is a single nucleotide polymorphism
(SNP) found at position 217 with either a T or a C. The maternal
parent is a heterozygote, with one allele being 217C and the
other, 217T, while the paternal parent is 217C (Figure 1D).
T7EN1, which cuts single-strand (unpaired) DNA, was unable
to cleave the denatured and renatured PCR products from the
father’s genomic DNA because they are all derived from the
same MECP2 allele (Figure 1D). However, the maternal DNA
has both 217T and 217C alleles, so when the genomic DNA
PCR product was denatured and renatured, mismatch at 217
could occur, generating a single-strand bubble that could then
be cleaved by T7EN1, generating two fragments (Figure 1D).
We then examined several tissues from the two miscarried
fetuses using this assay and detected multiple cleavage prod-
ucts, indicating the existence of mutations (Figure 1E). Because
both animals are male with one X chromosome inherited from
their mother, if no mutation is present the T7EN1 cleavage result
should be negative, as for the paternal DNA. However, our
T7EN1 cleavage assay on A and B fetus tail, brain, and testis
DNAs clearly indicated that they harbored de novo MECP2
mutations (Figure 1E). All three tissues from both animals
appeared to have many different kinds of MECP2 mutations
because the cleaved products formed multiple seemingly
smeary bands (Figure 1E). Through Sanger sequencing, we
confirmed that many alleles contained mutations, with some
insertions and deletions (in-dels), but mostly point mutations
(Figures 1F and 1G). We used maternal DNA as the reference
(because male fetuses acquire their X chromosomes from their
mother) and confirmed that point mutations detected were
indeed de novo mutations. From more than 50 DNA clones
sequenced from the brains of both fetuses (A and B), we found
that 35% and 22% of the clones in A and B, respectively, con-
tained mutations (Figure 1H). Using the same method, we
sequenced both maternal and paternal DNA from more than 50
clones each, and we detected no mutations, demonstrating
the validity of our approach for mutation analysis. Using
sequencing, T7EN1 cleavage, or both (Figures S2B and S2C),
we detected mutations in a range of different tissues including
the testes of both fetuses (Figures 1E–1H), making germlinecleavage assays. Since the paternal allele is homogenous, T7EN1 is incapable
allele), and thus in T7EN1 cleavage assay, positive digestionwas observed (two
, and testes tissues, indicative of the presence ofmutations at the targeted exon
n rate in the entire 351 bp exon. Mutation distribution plots were displayed for
in and tails of the fetuses.
al clones sequenced, we counted perfectly matched sequences with reference
ched sequences was calculated, we simultaneously acquired the mutation rate
ell Stem Cell 14, 323–328, March 6, 2014 ª2014 Elsevier Inc. 325
Figure 2. Generation of TALEN-Targeted
Live Cynomolgus Female Monkey
(A) Images of 3-month-old MECP2 mutant
cynomolgus with her mother.
(B) T7EN1 cleavage analysis of the placenta and
skin tissue of the female cynomolgus baby born
alive, indicative of the presence of mutations by
cleaved products (bracket with a star).
(C) Mutation distributions along the targeted exon 3
based on Sanger sequencing in placenta, skin, and
umbilical cord.
(D and E) Sequencing traits of nonsense mutations
detected in placenta and skins of the cynomolgus
female baby.
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we detected along the exon in each tissue and found that they
were spread across the entire length of exon 3 (Figure 1F). This
pattern differs from that seen in mutagenesis with single TALEN
pairs, suggesting that the use of three TALEN pairs simul-
taneously targeting the same exon influences the types and
positions of mutations that are elicited, potentially because of
interference or interaction between different TALENs targeting
simultaneously.
We have also applied our TALEN-targeting strategy in cyno-
molgus monkeys, which have an advantage over rhesus
monkeys in that they breed all year round rather than seasonally.
From a total of 54 embryos transferred into 19 cynomolgus
surrogates, we obtained 6 successful pregnancies, and subse-
quently 1 live birth of a female cynomolgus baby, which is
currently about 4 months old (Figure 1B). From the placenta,
the umbilical cord, and the skin biopsies, we detected a signifi-
cant degree of MECP2 mutagenesis as measured by T7EN1
cleavage assays and Sanger sequencing (Figures 2A–2E).
BecauseMECP2 is located on the X chromosome, manifestation
of genetic mutations in MECP2 depends on which allele is ex-
pressed. So far we have not observed any behavioral deficits
in this female monkey. However, because RTT patients usually
start to develop symptoms at 6–18 months after birth depending326 Cell Stem Cell 14, 323–328, March 6, 2014 ª2014 Elsevier Inc.on the severity of the disease, which is
related to the pattern of X chromosome
inactivation, it is possible that a longer
time will be needed for detection of the
phenotype. Recently, we saw miscarriage
of another cynomolgus fetus, which was
male and contained MECP2 mutations
(Figure S2D). So far, therefore, all three
of the midgestation-stage lethality events
have been for male fetuses carrying
MECP2 mutations. The high incidence
and similarity to human phenotypes sug-
gests that this embryonic lethality may
be an RTT-related phenotype.
Because we used one-cell embryo
cytoplasmic injection of circular plasmid
TALEN DNAs to induce mutagenesis, our
TALEN constructs likely had prolonged
expression in the form of episomal vectors
during early embryonic development(Iqbal et al., 2009). Continuous TALEN action and thus, repetitive
mutagenesis in the targeted region (in this case exon 3 of the
MECP2 gene), would undoubtedly create a high degree of
mosaicism in the resulting embryo. We also used three pairs of
TALENs to target the same MECP2 exon 3, which apparently
resulted in many point mutations across the entire targeted
exon, sometimes even slightly outside the TALEN arms. The
advantage of this approach is that it greatly increases the chance
of disrupting the targeted gene, including in the germline, but it
also leaves open a legitimate concern about whether mutations
occur elsewhere in the genome via off-target mutagenesis.
Compared to CRISPR/Cas9, TALENs are considered to have
much lower off-target activity (Ding et al., 2013; Ousterout
et al.; 2013). There are only a few reported cases of TALEN off-
target actions (Mussolino et al., 2011; Hockemeyer et al., 2011;
and Osborn et al., 2013). A new computational prediction tool
called TALENoffer successfully predicted five out of six reported
off-target events in the three aforementioned studies (Grau et al.,
2013). We therefore tested our three pairs of TALENs and all
possible cross-pair combinations to TALENoffer. A total of 41
exonic loci (with TALENoffer score > 1.8), 68 intronic loci
(with TALENoffer score > 1.6), and 5 intergenic loci (with
TALENoffer score > 1.4) were identified as potential off-target
sites (Table S1 available online). We then PCR amplified these
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donors, the surrogate mother, and the testes and brains of the
two miscarried fetuses, and examined them using Sanger
sequencing. A total of 798 samples were sequenced and no
mutations were detected (Table S1). In addition, we genotyped
the 41 exonic loci from 24 additional tissue samples of mis-
carried fetuses as well as the surviving female cynomolgus and
her parents. An additional 984 PCR products were sequenced
and again no mutations with confidence were detected (Table
S1). In sum, a total of 1,882 sequencings suggested no
‘‘off-target’’ effects beyond the targeted exonwith our approach.
In addition, as mentioned above, using TALEN-plasmid-specific
and Fok1-specific PCR of genomic DNAs from miscarried
fetuses, we confirmed that no TALEN plasmid genomic integra-
tions exist in our mutant monkeys (Figure S2A).
Overall, therefore, our study describes the successful applica-
tion of TALEN-mediated mutagenesis to produce MECP2
mutant monkeys and illustrates an approach that could open
up great opportunities in the future for the use of NHP models
to study and develop treatments for human diseases.
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